Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 3/20 | 0.57 |
| ▸ | PLK4 | O00444 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 11/20 | 0.51 |
| ▸ | GSK3B | P49841 | 7/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343410 | 0.87 | PAK4 (0.54) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL12105461 | 0.84 | AURKA (0.52) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL3852023 | 0.83 | GRK6 (0.42) | PAK4PLK4AURKAGSK3BAURKB | |
| SCHEMBL12102876 | 0.81 | MEN1 (0.52) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL22079284 | 0.81 | PAK4 (0.49) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL4788903 | 0.81 | PAK4 (0.49) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL5822082 | 0.81 | GRK6 (0.42) | PAK4PLK4AURKAGSK3BAURKB | |
| SCHEMBL3993234 | 0.81 | PAK4 (0.49) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL12102888 | 0.81 | GSK3B (0.50) | PAK4PLK4MEN1HTTKMT2A | |
| SCHEMBL24350501 | 0.80 | PIK3C3 (0.54) | PAK4PLK4MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665720-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024173832-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-3959213-B1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-111601804-B | Nitrogen-containing heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117355508-A | Heterocyclic derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-11439641-B2 | Pyrimidine JAK inhibitors for the treatment of skin diseases | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-13 | — | — | US | disclosed |
| WO-2022078305-A1 | HETEROCYCLIC DERIVATIVE AND MEDICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2022-04-21 | — | — | WO | disclosed |
| EP-3959213-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | Theravance Biopharma R&D IP, LLC (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2021016102-A1 | INHIBITORS OF TYROSINE KINASE | BRIDGENE BIOSCIENCES, INC. (US) | 2021-01-28 | — | — | WO | disclosed |
| US-20200338073-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-29 | — | — | US | disclosed |
| EP-1863797-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| WO-2007049041-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | WO | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| WO-2006106307-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006100461-A1 | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | disclosed |
| EP-1686999-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| EP-1678169-A1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005049033-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSYNE KINASES | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005040159-A1 | 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11439641-B2 | Pyrimidine JAK inhibitors for the treatment of skin diseases | JAK1, JAK3, JAK2 | PAK4 631/4885PLK4 1159/4885MEN1 4376/4885 |
| US-20200338073-A1 | PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | JAK1, JAK3, JAK2 | PAK4 631/4885PLK4 1159/4885MEN1 4376/4885 |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | IGF1R, IGFBP1, GPR119 | PAK4 2162/4885PLK4 2334/4885MEN1 2736/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | PAK4 437/4885PLK4 219/4885MEN1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.